New hope for elderly kidney cancer patients: drug safety checked
NCT ID NCT04416646
First seen Apr 17, 2026 · Last updated May 04, 2026 · Updated 3 times
Summary
This study observed 100 older adults (age 70+) with advanced kidney cancer to see how safe and effective the drug Cabozantinib is. The main goal was to track side effects. The study was completed, but it was observational, meaning it just watched what happened without giving a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istituto Oncologico Veneto
Padova, Italy, 35100, Italy
Conditions
Explore the condition pages connected to this study.